In a new study, de Souza and colleagues demonstrate the potent blood pressure lowering effect of low-dose spironolactone in patients with evident resistant hypertension. This finding should have ...

The landmark Randomized Aldactone Evaluation Study (RALES), published in 1999, showed that spironolactone, a potassium-sparing diuretic, improves outcomes in patients with severe heart failure.

Purpose: The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart ...